KLS Keeping Law Simple Legislation in plain English

Straight-ahead summaries built from the official bill text. We keep the source links front and center and leave the decision up to you.

Back to Maine

LD538 • 2025

An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives

An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives

Enacted

This bill passed the Legislature and reached final enactment based on the latest official action.

Sponsor
Representative Sally Cluchey
Last action
2025-05-29
Official status
Signed by the Governor
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives

An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives Sponsor: Representative Sally Cluchey Reference committee: Health Coverage, Insurance and Financial Services Governor action: Signed by the Governor

What This Bill Does

  • An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives Sponsor: Representative Sally Cluchey Reference committee: Health Coverage, Insurance and Financial Services Governor action: Signed by the Governor

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Amendments

These notes stay tied to the official amendment files and metadata from the legislature.

Adopted by House & Senate

Plain English: Page 1 - 132LR0749(02) COMMITTEE AMENDMENT 1 L.D.

  • Page 1 - 132LR0749(02) COMMITTEE AMENDMENT 1 L.D.
  • 538 2 Date: (Filing No.
  • H- ) 3HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES 4 Reproduced and distributed under the direction of the Clerk of the House.
  • 5STATE OF MAINE 6HOUSE OF REPRESENTATIVES 7132ND LEGISLATURE 8FIRST SPECIAL SESSION 9 COMMITTEE AMENDMENT “ ” to H.P.

Bill History

  1. 2025-05-29 Governor

    Signed by the Governor

  2. 2025-05-27 House

    PASSED TO BE ENACTED . Sent for concurrence. ORDERED SENT FORTHWITH.

  3. 2025-05-27 Senate

    PASSED TO BE ENACTED , in concurrence.

  4. 2025-05-15 Committee

    Reported Out; OTP-AM/ONTP

  5. 2025-03-26 Committee

    Work Session Held

  6. 2025-03-26 Committee

    Voted; Divided Report

  7. 2025-02-11 Committee

    Referred to Committee on Health Coverage, Insurance and Financial Services.

Official Summary Text

An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives
Sponsor:
Representative Sally Cluchey
Reference committee:
Health Coverage, Insurance and Financial Services
Governor action:
Signed by the Governor

Current Bill Text

Read the full stored bill text 
Page 1 - 132LR0749(03)
STATE OF MAINE
_____
IN THE YEAR OF OUR LORD
TWO THOUSAND TWENTY-FIVE
_____
H.P. 357 - L.D. 538
An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the
Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their
Generic Alternatives
Be it enacted by the People of the State of Maine as follows:
Sec. 1. 32 MRSA §13794, first ¶, as amended by PL 2019, c. 34, §5, is further
amended to read:
Every Except as authorized in this section, every drug dispensed pursuant to
prescription, whether for a legend drug or not, must carry on the label the following
information: the prescription number; the date of filling; the patient's name; directions for
use; the name and strength of the drug and the amount dispensed, including either the brand
name of the drug or, if a generic and therapeutically equivalent drug or interchangeable
biological product is dispensed the label must be in accordance with section 13781; the
beyond use date of the drug; the name of the practitioner prescribing the drug; and the
name, address and telephone number of the pharmacy where the prescription was
compounded and dispensed. For purposes of this section, "beyond use date" means a date
beyond which the contents of the prescription are not recommended to be used.
Sec. 2. 32 MRSA §13794, as amended by PL 2019, c. 34, §5, is further amended
by enacting at the end a new paragraph to read:
At the request of the practitioner prescribing the drug, the label for mifepristone,
misoprostol and their generic alternatives may include the name of the health care facility
that the practitioner is associated with instead of the name of the practitioner.
APPROVED
MAY 29, 2025
BY GOVERNOR
CHAPTER
142
PUBLIC LAW